One Drop lands CE mark for AI-powered blood glucose prediction for diabetes
17 May 2021 --- One Drop has received the Conformité Européenne (CE) Mark for its blood glucose prediction analysis engine, which can accurately forecast glucose levels up to eight hours in advance for people living with prediabetes, Type 2 diabetes and gestational diabetes.
“Obtaining the CE Mark for One Drop's glucose forecasts is a critical quality, safety and regulatory milestone in making artificial intelligence (AI)-powered, prospective self-care the first choice for addressing precision health in chronic conditions,” says Dan Goldner, One Drop’s senior vice president of data science.
Jeff Dachis, CEO and founder, adds that this recognition helps the company’s goal to transform health, change lives and create opportunities.
“By empowering people living with chronic conditions to finely tune their decisions, One Drop sets them on the path to better health outcomes, peak performance and a more fulfilling life,” he says.
Harnessing AI
Unlike other digital health solutions, which apply machine learning to backend infrastructure, One Drop uses AI to support people directly with immediate insights they can use.
Users received glucose forecasts paired with real-time advice for exercise, diet and lifestyle adjustments.
“For any AI solution to be successful, it requires a vast amount of data. One Drop has been intentional about investing in data since the beginning, and today, many of our competitors have yet to achieve 1 percent of our data wealth,” adds Goldner.
Because One Drop's algorithms rely on One Drop's data wealth rather than continuous glucose testing, the AI-powered feature can significantly reduce the need for fingerstick glucose checks.
Digital membership subscribers of One Drop can also access one-on-one coaching with a certified health professional, interactive educational content and health data tracking tools.
Collecting billions of data points
One Drop first introduced glucose predictions to the member experience in 2018. To date, it has collected nearly 25 billion longitudinal health data points across 75 biomarkers from millions of users in 195 countries.
The One Drop app collects glucose, weight, blood pressure, food, medications and physical activity through manual input, passively collected connected medical devices (e.g., One Drop meter), and direct integrations with HealthKit, GoogleFit, Dexcom, Fitbit, Apple Watch and Companion Medical.
It is also developing a multi-analyte dermal sensor that will generate thousands of valuable new data points per member per day.
The company's data trains the proprietary machine learning algorithms behind One Drop's eight-hour glucose forecasts, predictive capabilities for people using continuous glucose monitoring and long-term outcomes forecasts for diabetes-related biomarkers.
Spotlight on glucose monitoring
According to the company, 94 percent of its members who provided survey feedback found glucose forecasts and insights helpful. Glucose forecasts and insights simplify healthy decision-making by connecting everyday behaviors with outcomes and offer ongoing guidance to complement the support consumers receive from their healthcare provider.
Last month, Pendulum Therapeutics raised US$54 million for its products targeting the microbiome, including to help control blood sugar spikes.
Glucose monitoring is also attracting attraction from the sports nutrition sector, as seen with Abbott launching the Libre Sense Glucose Sport Biosensor. Earlier this year, engineers also developed a skin patch that tracks blood pressure, heart rate and glucose levels while measuring either the wearer’s lactate, alcohol or caffeine levels.
Edited by Katherine Durrell
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.